| Bioactivity | (E/Z)-Elafibranor ((E/Z)-GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively[1][2][3]. |
| Target | EC50: 45 nM (PPAR-α), 175 nM (PPAR-δ) |
| CAS | 824932-88-9 |
| Formula | C22H24O4S |
| Molar Mass | 384.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu ZM, et al. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Expert Opin Investig Drugs. 2015 May;24(5):611-21. [2]. Ratziu V, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016 May;150(5):1147-1159. [3]. Hanf R, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.Diab Vasc Dis Res. 2014 No |